Viyash Scientific VIYASH.NS · INR

Its shares trade on NSE under the ticker VIYASH.NS. It has been listed since 10 March 2016. In the fiscal year to 31 March 2025, it reported revenue of ₹15.51bn and net income of ₹218.8m. At that date it held total assets of ₹16.02bn and shareholders' equity of ₹7.04bn.

SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2016-03-10. The firm provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The firm operates through the pharmaceuticals segment. The firm is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. The company is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. The company provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. Its subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Kamal SharmaIndependent Non-Executive Chairman of the Board₹3.4m
• Mr. Rajaram NarayananChief Executive Officer, Managing Director, Executive Director, since 2022₹19.9m
• Mr. Saurav BhalaChief Financial Officer
• Ms. Yoshita VoraCompany Secretary and Compliance Officer
• Mr. Prasad LadVice President - Human Resources and Admin
• Mr. Pankaj LohanVice President, Head - India Formulations
• Mr. Vedprakash RagateExecutive Director, since 2024
• Mr. Yawar AbbasEmerging Markets
• Mr. Alexis GouxGlobal Formulations
• Mr. Ashish KakabaliaBusiness Development and Research & Development
• Mr. Alan KellyUnited States Operations
• Mr. Murat MentesTurkey Operations

Overall

48

Environment

40

Social

58

Governance

47

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.